Clinical trial
First-in-Human (FIH) Study of the Xeltis Hemodialysis Access Graft (aXess)
NCT04898153 is registered in ClinicalTrials.gov with Xeltis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- First-in-Human (FIH) Study of the Xeltis Hemodialysis Access Graft (aXess)
- Lead sponsor
- Xeltis
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- June 10, 2021
- Completion date
- September 30, 2027
- Enrollment
- 20 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
end stage renal disease, end stage renal failure on dialysis